CAT BITE Antibiotic Prophylaxis for the Hand/Forearm (CATBITE)

Launched by UNIVERSITY OF MISSOURI-COLUMBIA · Apr 26, 2023

Keywords

ClinConnect Summary

The CAT BITE clinical trial is studying the best way to prevent infections after a cat bite to the hand or forearm. Cat bites can lead to serious infections because they often introduce bacteria from the cat's mouth into the skin. The trial will compare different lengths of antibiotic treatment—either a placebo (no medication), a one-day course, or a five-day course of an antibiotic called amoxicillin-clavulanate. Researchers hope to find out if shorter antibiotic use is just as effective as the longer courses, which could help reduce unnecessary medication.

To participate in this study, you need to be at least 18 years old and have been bitten by a cat on your hand or forearm within the last 24 hours. You should not have any existing infections or have taken antibiotics in the past 30 days. If you join the study, you will receive either the placebo or the antibiotic for a specified period, and you’ll be monitored to check for infections and any side effects. This important research could change how we treat cat bites in the future, making it safer and easier for patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients greater or equal to 18 years of age.
• • Bitten by a cat.
• • Location of bite is the hand and/or forearm (distal to elbow).
• • Presenting \<24 hours following a cat bite to the hand/forearm.
• • English speaking
• Exclusion Criteria:
• • Patients who present with active local or systemic infections
• • 1. Purulent drainage from the cat bite
• • 2. Redness AND swelling at the location of the cat bite
• • Having a fever \>100.4° F or \>38° C)-Received antibiotics within the past 30 days
• • Received antibiotics within the past 30 days
• • Patients unwilling to take study medication
• • Patients unwilling to attend scheduled follow-up evaluations or complete study forms
• • Pregnant Women
• • Type I hypersensitivity reaction to any of the study interventions
• • Immunocompromised patients (primary and secondary immunodeficiencies) Primary
• • Autoimmune Lymphoproliferative Syndrome (ALPS)
• • Autoimmune Polyglandular Syndrome type 1 (APS-1)
• • B-cell Expansion with Nuclear factor kappa-light-chain-enhancer of activated B cells and T-cell Anergy (BENTA) Disease
• • Caspase Eight Deficiency State (CEDS)
• • Caspase Recruitment Domain Family Member 9 (CARD9) Deficiency and Other Syndromes of Susceptibility to Candidiasis
• • Cartilage-hair hypoplasia
• • Chédiak-Higashi syndrome
• • Chronic Granulomatous Disease (CGD)
• • Common Variable Immunodeficiency (CVID)
• • Complement Deficiencies
• • Congenital Neutropenia Syndromes
• • Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA4) Deficiency
• • Cyclic neutropenia
• • DiGeorge syndrome
• • Dedicator Of Cytokinesis 8 (DOCK8) Deficiency
• • GATA-binding protein 2 (GATA2) Deficiency
• • Glycosylation Disorders with Immunodeficiency
• • Hyper-Immunoglobulin E Syndromes (HIES)
• • Hyper-Immunoglobulin M Syndromes
• • Interferon Gamma, Interleukin 12 and Interleukin 23 Deficiencies
• • Leukocyte Adhesion Deficiency (LAD) Types 1 and 2
• • Lipopolysaccharide Responsive Beige-Like Anchor Protein (LRBA) Deficiency
• • Phosphatidylinositol 3-kinase (PI3-Kinase) Disease
• • Phospholipase C gamma 2 (PLCG2) associated Antibody Deficiency and Immune Dysregulation (PLAID)
• • Severe Combined Immunodeficiency (SCID)
• • Selective Immunoglobulin A (IgA) deficiency
• • Signal transducer and activator of transcription 3 (STAT3) Dominant-Negative Disease
• • STAT3 Gain-of-Function Disease
• • Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) Syndrome
• • Wiskott-Aldrich Syndrome (WAS)
• • X-Linked Agammaglobulinemia (XLA)
• • X-Linked Lymphoproliferative Disease (XLP)
• • X-linked magnesium transporter 1 (MAGT1) deficiency with increased susceptibility to Epstein-Barr virus (EBV) infection and N-linked glycosylation defect (XMEN) Disease
• • Zeta-associated protein 70 (ZAP-70) deficiency
• • Secondary
• • Malnutrition
• • Uncontrolled Diabetes mellitus
• • Chronic uremia
• • Genetic syndromes: trisomy 21
• • Immunomodulatory, immunosuppressive drug therapy: corticosteroids, calcineurin inhibitors, cytotoxic agents
• • Systemic lupus erythematosus
• • Malignancy
• • Active radiation therapy
• • Bone marrow ablation
• • Infectious diseases: human immunodeficiency virus (HIV) infection, Hepatitis
• • Additional Primary and secondary immunodeficiencies can be found at the following link.
• • https://www.merckmanuals.com/professional/immunology-allergic-disorders/immunodeficiency-disorders/overview-of-immunodeficiency-disorders